New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
09:59 EDTMGLN, VRTS, DYAX, SBNY, BCRX, NCI, EPEOn The Fly: Analyst Initiation Summary
Magellan Health (MGLN) initiated with a Market Perform at Leerink... Virtus Investment Partners (VRTS) initiated with a Neutral at BofA/Merrill... Signature Bank (SBNY) coverage resumed with a Buy at Goldman... Dyax (DYAX) initiated with an Outperform at Oppenheimer... BioCryst (BCRX) initiated with a Perform at Oppenheimer... Navigant Consulting (NCI) initiated with a Buy at UBS... EP Energy (EPE) initiated with an Equal Weight at Morgan Stanley.
Check below for free stories on MGLN;VRTS;DYAX;SBNY;BCRX;NCI;EPE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
12:49 EDTMGLNMagellan Health management to meet with Jefferies
Subscribe for More Information
September 15, 2014
07:03 EDTDYAXDyax announces issuance of two DX-2930 U.S. patents
Subscribe for More Information
September 8, 2014
15:01 EDTSBNYSignature Bank management to meet with Sterne Agee
Meeting to be held in New York on September 10 hosted by Sterne Agee.
September 7, 2014
12:42 EDTBCRXBioCryst announces RAPIVAB trial results for the treatment of influenza
Subscribe for More Information
September 5, 2014
10:57 EDTBCRXBioCryst falls after WHO posts document on potential Ebola therapies
Shares of BioCryst Pharmaceuticals (BCRX) are sliding in early trading after the World Health Organization posted documents ahead of a meeting it is holding to discuss the recent Ebola outbreak and potential strategies to combat the disease. WHAT'S NEW: This week, on September 4-5, WHO is bringing together technical experts from the groups developing Ebola interventions along with people working to overcome Ebola virus disease, the group stated on its website. WHAT'S NOTABLE: In a background document on potential Ebola therapies and vaccines, WHO wrote regarding the availability and feasibility of BCX4430 from Biocryst that the drug "needs animal treatment and protection data for EVD before it can be considered. No material is currently available for field use." PRICE ACTION: Shares of BioCryst are down 50c, or 3.76%, to $12.28. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use